Please use this identifier to cite or link to this item: https://doi.org/10.1158/2159-8290.CD-12-0595
Title: PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy
Authors: Tan, J.
Li, Z.
Lee, P.L.
Guan, P.
Aau, M.Y.
Lee, S.T.
Feng, M.
Lim, C.Z.
Lee, E.Y.J.
Wee, Z.N.
Lim, Y.C.
Karuturi, R.K.M.
Yu, Q. 
Issue Date: Oct-2013
Citation: Tan, J., Li, Z., Lee, P.L., Guan, P., Aau, M.Y., Lee, S.T., Feng, M., Lim, C.Z., Lee, E.Y.J., Wee, Z.N., Lim, Y.C., Karuturi, R.K.M., Yu, Q. (2013-10). PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. Cancer Discovery 3 (10) : 1156-1171. ScholarBank@NUS Repository. https://doi.org/10.1158/2159-8290.CD-12-0595
Abstract: Although 3-phosphoinositide-dependent protein kinase-1 (PDK1) has been predominately linked to the phosphoinositide 3-kinase (PI3K)-AKT pathway, it may also evoke additional signaling outputs to promote tumorigenesis. Here, we report that PDK1 directly induces phosphorylation of Polo-like kinase 1 (PLK1), which in turn induces MYC phosphorylation and protein accumulation. We show that PDK1-PLK1-MYC signaling is critical for cancer cell growth and survival, and small-molecule inhibition of PDK1/PLK1 provides an effective approach for therapeutic targeting of MYC dependency. Intriguingly, PDK1-PLK1-MYC signaling induces an embryonic stem cell-like gene signature associated with aggressive tumor behaviors and is a robust signaling axis driving cancer stem cell (CSC) self-renewal. Finally, we show that a PLK1 inhibitor synergizes with an mTOR inhibitor to induce synergistic antitumor effects in colorectal cancer by antagonizing compensatory MYC induction. These findings identify a novel pathway in human cancer and CSC activation and provide a therapeutic strategy for targeting MYC-associated tumorigenesis and therapeutic resistance. SIGNIFICANCE: This work identifies PDK1-PLK1-MYC signaling as a new oncogenic pathway driving oncogenic transformation and CSC self-renewal. Targeted inhibition of PDK1/PLK1 is robust in targeting MYC dependency in cancer cells. Thus, our findings provide important insights into cancer and CSC biology and have significant therapeutic implications. © 2013 American Association for Cancer Research.
Source Title: Cancer Discovery
URI: http://scholarbank.nus.edu.sg/handle/10635/115861
ISSN: 21598274
DOI: 10.1158/2159-8290.CD-12-0595
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

43
checked on Jun 20, 2018

WEB OF SCIENCETM
Citations

38
checked on Jun 20, 2018

Page view(s)

51
checked on Jun 22, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.